ACW conducts Type C meeting with FDA regarding depression
Filed with ASX · · 3 pages · English
Actinogen Medical Limited on 6ix
In the deck
Earlier from Actinogen Medical
- ACW HY25 results Advancing to latestage clinical development
- Peer-reviewed clinpharm manuscript published
- ACW December 2024 quarterly activity report & Appendix 4C
- ACW randomizes first US participant in Alzheimers trial
- Actinogen receives $9.0 million R&D tax incentive rebate
Later from Actinogen Medical
- Actinogen March 2025 quarterly activity report & Appendix 4C
- Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news
- ACW 100th AD trial participant & interim analysis timeline
- ACW accesses up to $13.8m in non-dilutive R&D tax funding
- Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical